Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medicinova (MNOV) Change in Accured Expenses (2021 - 2025)

Medicinova (MNOV) has disclosed Change in Accured Expenses for 7 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses changed N/A to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $428237.0, a N/A change, with the full-year FY2025 number at $459871.0, up 247.23% from a year prior.
  • Change in Accured Expenses was $1.1 million for Q4 2025 at Medicinova, up from -$812979.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.1 million in Q4 2025 to a low of -$1.4 million in Q4 2021.
  • A 5-year average of -$89217.3 and a median of $15439.5 in 2023 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: crashed 512.43% in 2023, then skyrocketed 500.17% in 2024.
  • Medicinova's Change in Accured Expenses stood at -$1.4 million in 2021, then soared by 108.21% to $111353.0 in 2022, then soared by 328.29% to $476913.0 in 2023, then plummeted by 75.84% to $115246.0 in 2024, then soared by 876.57% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for MNOV's Change in Accured Expenses are $1.1 million (Q4 2025), -$812979.0 (Q1 2025), and $115246.0 (Q3 2024).